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be seen as blocking access. As the marginal cost (MC) of a new product is lower than 
the charged price there is a well-known waste. One option is to establish a two-part 
pricing model with a “subscription” price plus a usage price close to MC. The objec-
tive of this paper is to provide an economic analysis based on theories and concepts 
from microeconomics and industrial organization of two-part pricing in the market 
for patent protected medicines (PPM). Methods: The situation will be analyzed from 
a game theoretical and an empirical perspective. The starting point is the Swedish 
Health Care system with focus on oncology. A two-part pricing contractual arrange-
ment will also be discussed for some other EU countries. Results: Demand side 
consists of a publicly funded local buyer who represents a large number of potential 
users. This often leads to a bargaining solution where price is below the one set by a 
standard monopoly. A two-part pricing - where the buyer pays a substantial fixed-fee 
to get access to the PPM and a per unit price equal to marginal cost – may increase 
efficiency. However, numerous issues need to be taken into account when consider-
ing introducing two-part pricing, for example uncertainty and risk, the operation on 
many markets, free-riders and reselling. ConClusions: Quantities are unlikely to 
be efficient with the current pricing model in the Swedish oncological market. A two-
part pricing is likely to increase the efficiency in such markets but is also associated 
with some serious challenges.
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objeCtive: To introduce the development of Chinese pediatric medicine, and based 
on foreign experiences propose some measures that China should take immediately 
for improving the access to pediatric medicine and promote Chinese innovation 
for pediatric medicine. Methods: Data were mainly obtained from the National 
Bureau of Statistics of China, the open Chinese government documents and some 
published papers. Apply descriptive statistics and comparison to summarize poli-
cies’ lacks and propose some suggestions. Results: In 2013, there are 220 million 
Children under 14 years old who account for 16.4% of total Chinese population. In 
the 2009 National Reimbursement Drug List, the number of pediatric medicines 
is about 60 and accounts for 1.52% in all 3500 drugs, 80% of which does not have 
usage information of “exclusive pediatric medicine”, 90% of which does not have 
pediatric formulation. Adverse reaction rate of pediatric medicine is 12.9%, which is 
obviously higher than adult medicine. ConClusions: China should immediately 
take some incentive measures to encourage the innovation of pediatric medicines 
based on foreign experiences
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Incorporating the patient perspective on the value of medicines into health tech-
nology assessments (HTA) is becoming increasingly important as acknowledged 
by several prominent HTA agencies. NICE (UK) has employed several measures, 
including a Citizen’s Council. Canada, particularly in the area of oncology, has a 
formalized process through which patient input on drug reviews and feedback 
on recommendations is obtained to ensure patients’ experiences (both good and 
bad) of living with cancer and undergoing treatment are routinely considered. 
In Australia, there is a consumer representative on the Pharmaceutical Benefits 
Advisory Committee (PBAC) and patients have the opportunity to provide written 
input during the assessment process, although the process of how PBAC consider 
and incorporate this information into their decision is not transparent. There is a 
need for a more formalized framework for eliciting meaningful patient input and 
a more transparent process for how that input is incorporated into the decision 
making process. This research seeks to outline a novel methodological approach 
to elicit and quantify patient values in a systematic way for the purpose of treat-
ment evaluation (Patient Value Mapping). The focus of this research is Chronic 
Lymphocytic Leukemia (CLL) and involves patient participation in multiple research 
stages. Stage 1 involves conducting exploratory qualitative interviews and semi-
structured quantitative surveys to gauge how patients view treatments and what 
outcomes are most important to them. Stage 2 quantifies the insights from stage 
1 using discrete choice based methods, including measuring the relative weight-
ings of importance on each of the outcomes and the associated willingness to pay. 
Current and proposed treatments are entered into the resulting model and scored 
based on how well they align with patient values and expectations. The results of 
this analysis could be incorporated into the HTA evaluation process and used to 
guide decisions around the value of new medicines.
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objeCtives: Traditionally, business-related projects are either executed by employ-
ees within an organization or outsourced to external vendors. Crowdsourcing, on 
the other hand, allows sponsors to leverage the Internet to draw upon the skills 
and experiences of the public in open forums to generate new ideas or deliverables. 
Crowdsourcing for healthcare technology innovation has become increasingly popu-
lar; however, the type of stakeholders involved and healthcare technologies sought 
are not well understood. The aim of this study is to characterize crowdsourcing 
competitions focused on healthcare technology innovation. Methods: Information 
was gathered from the Health 2.0 Developer Challenge website, a leading online 
competition platform where complex healthcare challenges are crowdsourced by 
sponsoring agencies to teams of developers. Completed challenges listed on the 
platform from January 2007-October 2014 were identified. For each challenge, total 
prize money, stakeholder type, and challenge theme were examined. Results: 
A total of 57 challenges were identified with $3.31 million awarded as total prize 
money (mean= $75,250; median= $40,000; max= $750,000). Government agencies 
sponsored the majority of challenges (46%), followed by non-profit (37%) and 
for-profit (25%) organizations. Four (7%) challenges were sponsored by pharma-
ceutical companies and accounted for 14% of total prize money (mean= $117,500; 
median= $150,000; max= $160,000). The five most common challenge themes iden-
tified were data management (25%), enhanced decision making (16%), communi-
cation barrier (14%), health education (14%), wellness/tracking (11%), and disease 
prevention/screening (11%). ConClusions: Although government agencies were 
the most common sponsors of crowdsourced healthcare technology challenges, 
pharmaceutical companies offered the highest mean monetary awards. Data man-
agement solutions (e.g. electronic health record applications) were the most fre-
quently solicited theme among all challenges. Crowdsourcing shows promise as a 
source of innovative healthcare technology solutions; however, more research is 
needed to explore the viability of such solutions.
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objeCtives: MCDA provide innovative approaches to measure the value of inter-
ventions and support decision making. A broad range of criteria are used to integrate 
big data and reflect the various constraints under which healthcare decisions are 
made. The objective of this study was to analyze the ethical theories and principles 
embedded in the criteria of holistic MCDA. Methods: EVIDEM was selected as a 
holistic framework aiming at defining value, or goodness, of healthcare interven-
tions, in its widest sense (axiology), i.e., encompassing their effects on health of 
patients, populations and healthcare systems. Each criterion of the framework was 
analyzed regarding its ethical background theories, inherent norms, values, and 
associated principles, and ethical implications. A broad range of ethical theories and 
positions were considered including virtue ethics, deontology, consequentialism, 
utilitarianism, theory of justice, human rights, and principlism. Results: Criteria 
related to healthcare intervention outcomes (“Effectiveness”, “Safety”, “Patient-
reported outcomes”, Type of benefit) are expressed in the Hippocratic Oath and 
rooted in deontology (imperative to help), principlism (autonomy, beneficence, non-
maleficence), and also in consequentialism. “Disease severity“, “Unmet needs” and 
“Priorities” are related to the theory of justice to prioritize those who are worst 
off, but also to deontology and virtue ethics. “Size of population” is rooted in utili-
tarianism pursuing the greatest good for the greatest number. Economic criteria 
as an inherent part of value appraisal ensure wise use of resources (virtue ethics 
[practical wisdom]) to maximize health under limited resources based on social 
responsibility (utilitarianism). “Affordability and Opportunity costs” and “System 
capacity and appropriate use” are related to consequentialism while “Political/his-
torical/cultural” and “Stakeholders pressure/barriers” are rooted in virtue ethics and 
human rights. ConClusion: Holistic MCDA systematically incorporates a broad 
range of ethical perspectives, norms, values and principles, and as such is a norma-
tive approach for prioritizing healthcare interventions that optimize patients’ and 
healthcare systems health.
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objeCtives: Electronic Healthcare databases and use of machine learning algo-
rithms has created opportunities for rapid learning. However, the indiscriminate 
application of machine learning algorithms to non-experimental healthcare 
databases may result in incorrect inferences about possible treatment benefits. 
This paper compares results from large healthcare databases produced by sta-
tistical, machine learning, and hybrid methods to emphasize the importance 
of controlling for known biases in healthcare databases and machine learning 
algorithms. Methods: MS patient cases were selected from an EMR database 
that met the following criteria: Must be on an MS therapy for at least one year 
and diagnosed with at least one co morbidity prior to and during the treatment 
period. Co morbidity improvements are measured by changes in specific lab val-
ues measured prior to and during treatment. To facilitate method comparison, a 
binary variable was constructed to measure improvements in co morbidities expe-
rienced during MS therapy. Treatment groups were defined by specific MS thera-
pies and compared to control groups treated with alternative therapies during 
the observation period. Propensity scores were used with all methods. Statistical 
and machine learning algorithms were compared to a hybrid algorithm, SIDES, 
originally designed for subpopulation analysis in RCT’s while controlling for multi-
plicity bias (Lipkovich et al. 2011). Results: Initial analyses identified differences 
in predictors of co mobidity improvements. The presentation will cover specific 
comparisons between different methods, highlight similarities and differences 
in findings and provide rationales for divergent results. ConClusion: Machine 
learning methods (such as SIDES) designed for use in RCTs can be adapted for use 
with large healthcare databases to accelerate learning and discovery while also 
including protections against known sources of bias in healthcare data (treat-
ment selection) and machine learning methods (multiplicity) that can lead to 
incorrect inferences.
